News



Update on the restructuring of the AB Science clinical development department in 2018
19/12/2018 - AB Science provides the main achievements of this restructuring

AB Science announces that the masitinib phase 3 study in Alzheimer's disease has completed patient recruitment
22/10/2018 - Final results will be available in 2019.

AB Science announces the publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral Sclerosis
08/10/2018 - Results published in the Journal of Clinical Investigation Insight further strengthen the body of evidence for masitinib's mode of action in ALS

First half of 2018 revenues
01/10/2018 - AB Science reports its revenues for the first half of 2018 and provides an update on its activities

AB Science reports positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer
23/07/2018 - A trend analysis for OS was planned after a certain number of events are observed

Results of the Combined General Shareholders' Meeting held on June 29 2018
03/07/2018 - The voting details for each resolution are available in the Investor Relations section of the website

Combined General Shareholders' Meeting held on June 29, 2018
03/07/2018 - Presentation of the current situation and future prospects

AB Science reports positive IDMC recommendation based on an interim analysis of the masitinib phase 3 study in first-line treatment of castrate-resistant prostate cancer
19/06/2018 - AB Science expects study to be completed in 2019

AB Science provides update on EU marketing authorization application for masitinib in the treatment of amyotrophic lateral sclerosis
28/05/2018 - AB Science is evaluating the possibility to resubmit the application based on the final results from study AB10015

Annual Financial Results as of December 31, 2017
30/04/2018 - AB Science reports on its annual financials as of 31 December 2017 and provides an update on its activities

AB Science announces that the CHMP has adopted a negative opinion for the marketing authorization of masitinib in Amyotrophic Lateral Sclerosis
19/04/2018 - AB Science will provide additional data through a reexamination procedure

Corporate Presentation
13/03/2018 - Current status and perspective for 2018

AB Science announces that based on interim analysis, IDMC recommended the continuation of the masitinib phase 3 study in progressive forms of multiple sclerosis with no requirement to increase the study sample size
04/01/2018 - Additionally, the IDMC did not report any safety concern with masitinib in the study population